Compare Mesoblast Limited (MESO) vs StandardAero Inc. Common Stock (SARO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs StandardAero Inc. Common Stock — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.80B), while StandardAero Inc. Common Stock trades at $19.7 (market cap $6.54B). The key difference: StandardAero Inc. Common Stock is far larger — about 3.6× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (225,551 versus 2,352,783). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and StandardAero Inc. Common Stock for 0 Days on average.
| MESO | SARO | |
|---|---|---|
Market Cap | $1.80B | $6.54B |
Volume | 225,551 | 2,352,783 |
Sector | Health | Industrials |
52-Week High | $20.96 | $33.12 |
52-Week Low | $13.19 | $19.76 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.88B | $8.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About StandardAero Inc. Common Stock
StandardAero, Inc. is an independent provider of aircraft engine maintenance, repair, and overhaul services, supporting commercial, military, and business aviation customers across more than 40 engine platforms.
Read more on SARO →
